Single-Cell Transcriptomic Identification of Novel MMP and TLR4 Inhibitors for Rheumatoid Arthritis via Synovial Bioactivity Profiling
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Companion research paper to provisional patent application disclosing computational drug repurposing candidates for rheumatoid arthritis. Single-cell RNA sequencing data from RA synovial tissue (GSE200815, n=9 donors) and osteoarthritis control (GSE152805, n=9 donors) were analyzed using scVI variational autoencoder dimensionality reduction, Leiden clustering, and Wilcoxon differential expression. 11,722 significant differentially expressed genes were identified across 10 inflammatory synovial cell populations (90,781 cells). Top DE genes included PRG4, CD74, HLA-DRA, APOE, and IFI27, reflecting FLS activation, antigen presentation, and interferon signaling. ChEMBL multi-target bioactivity screening yielded 842 patent-novel NOVEL_ALL candidates. Three independent MMP1/MMP2/MMP3 inhibitors ranked at the top, mechanistically coherent with PRG4 upregulation as the dominant FLS signal. Five TLR4 inhibitors were identified as a secondary therapeutic axis. Authors: Glen Charles Ritschel (Ritschel Research, Tega Cay SC) and Claude (Anthropic, San Francisco CA).
Fields of Study & Subjects
Rheumatoid Arthritis Research and Therapies
Computational Drug Discovery Methods
Natural Compounds in Disease Treatment
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 30 March 2026
- Language
- EN
- Document type
- Preprint